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ABSTRACT
Objectives: Labor-induction methods are used in about 23% of labors. Most commonly, pharmacological methods are 
used to pre-induct the labor with dinoprostone — a PGE2 analog, and misoprostol — a PGE1 analog. The aim of this study 
was to evaluate two pharmacological methods of labor induction with the use of prostaglandins applied via an intravagi-
nal insert containing misoprostol at a dose of 0.2 mg and intracervical gel containing dinoprostone at a dose of 0.5 mg.
Material and methods: This retrospective study was conducted on a group of 50 adult patients qualified for the pre-induc-
tion of labor. Following data were recorded: the time from the drug administration to the beginning of regular contractile 
function, the time from administration to amniotic fluid rupture, the time from medicament administration to the vaginal 
labor or caesarean section, the duration of I, II and III stages of labor, the delivery method and in the event of caesarean sec-
tion — the indications for surgery.
Results: In comparison to dinoprostone, the misoprostol application was found to shorten the time from drug administra-
tion to amniotic fluid rupture by 14.1 hours, the time to the beginning of the first stage of labor by 11.7 hours and from the 
drug administration to the delivery by 17.3 hours (p-value < 0.05). The duration of the first stage of labor in the misoprostol 
group was shorter by 1.2 hours than in dinoprostone group (p-value < 0.05).
Conclusions: Application of intravaginal insert with misoprostol at a dose of 0.2 mg appears to be a more effective method 
of labor induction in comparison to intracervical gel with dinoprostone at a dose of 0.5mg. Thorough analysis of these 
methods requires further studies. 
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INTRODUCTION
Induction of labor is one of the most commonly per-
formed procedures in obstetrics. This is a process for the 
commencement of delivery when the risk of pregnancy 
continuation exceeds the potential risk of its completion 
before the appearance of spontaneous contractile func-
tion. Based on the national registries in Great Britain and 
the United States, it is estimated that in developed coun-
tries the pregnancy rate, in which any method of induc-
tion is being used, is about 23% [1]. Moreover, in recently 
reported research on the American population the rate of 
induced births turns out to be even higher — 42.9% and 
31.8% for the primigravidas and multigravidas, respectively. 
There is a correlation between the use of labor induction 
and perinatal results, in particular in reducing the perinatal 
maternal-fetal mortality, as well as in the percentage of 
surgical births [2, 3].
The use of pharmacological or mechanical methods 
for labor induction occurs when there is no spontaneous 
regular contractile function with preserved amniotic sac. 
The effectiveness of this depends on a proper preparation 
of the cervix. It turns out that the higher failure rate of la-
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bor induction is associated with a low grade on the Bishop 
scale  [2]. Synthetic prostaglandins have a proven effect 
on the uterine cervix in labor induction as they increase 
smooth muscle fiber contractility and accelerate cervical 
ripening [4]. According to data, the use of prostaglandins in-
creases the probability of spontaneous delivery and reduces 
the need for subsequent doses of oxytocin without increas-
ing the proportion of caesarean sections [5]. Nevertheless, 
there is an increased risk of excessive contractile function 
(hyperstimulation) associated with this method. Currently, 
the most commonly used drug to pre-induct the labor is 
dinoprostone, which is a PGE2 analog and misoprostol, 
aPGE1 analog [6].
Misoprostol can be applied via an intravaginal insert, 
a rectal suppository or an oral tablet. Dinoprostone occurs 
in intravaginal systems and in a form of an intracervical gel. 
There are many publications available in literature on the ef-
fectiveness of different forms of prostaglandins administra-
tion [4]. It should be noted, however, that the vast majority 
of researches use misoprostol in the form of tablets given 
vaginally in the scheme, which in Poland is currently used 
only for the induction of abortion or stillbirth. Therefore, the 
only acceptable form of the labor induction is currently the 
use of intravaginal inserts containing misoprostol at a dose 
of 0.2 mg. Likewise, in Poland the only available form of ad-
ministration of dinoprostone is via intracervical gel at a dose 
of 0.5mg. So far, there were only a few studies carried out to 
compare these two methods of labor induction. 
OBJECTIVES
The aim of this study was to evaluate equally applied 
pharmacological methods of labor induction with the use 
of prostaglandins in the third degree reference center by 
using intravaginal insert containing misoprostol at a dose 
of 0.2 mg and intracervical gel containing dinoprostone at 
a dose of 0.5 mg.
MATERIAL AND METHODS
This was a retrospective study conducted on a group of 
50 adult patients admitted to the Department of Obstetrics 
and Perinatology in their third trimester of pregnancy in 
the perinatal period. The inclusion criteria was the age of 
pregnancy between 37–41 weeks and that the patients 
qualified for pre-induction due to the duration and the 
biological maturity of pregnancy in the absence of spon-
taneous contractile function. In all the patients, the cervix 
maturity was found to be less than 4 points in the Bishop’s 
scale at the time of medication administration. The exclu-
sion criteria were: premature rupture of membranes or any 
known contraindication to vaginal birth [7].
Patients were divided in two groups to undergo labor 
pre-induction by intracervical administration dinoprostone 
gel at a dose of 0.5 mg or intravaginal insert of misopros-
tol at a dose of 0.2 mg. In the absence of contractile func-
tion the intracervical Foley catheter was administered. The 
time interval between the two methods was approximately 
24 hours. Following medicament administration each patient 
had 2 hours bed regime and cardiotocography (CTG) was 
performed. In case of contractile function development the 
patient was examined every two hours or more frequently if 
any indications emerged. The following data were recorded: 
the time from the drug administration to the beginning of 
regular contractile function, the time from administration to 
amniotic fluid rupture, the time from medicament adminis-
tration to the vaginal labor or caesarean section, the duration 
of I, II and III stages of labor, the delivery method and in the 
event of caesarean section — the indications for surgery.
The statistical analysis was conducted using Statistica 
v. 10.0. The results were analyzed in order to determine 
the statistically significant differences between the two 
groups. The differences were considered statistically sig-
nificant at the confidence p-value below 0.05.
RESULTS
The study groups involved 50 patients. The median age 
of patients included in this study was 31 years (min. 19, max. 
41). The characteristics of the group are shown in Table 1. 
The U Mann-Whitney test was used to estimate the 
significant differences between the groups for the follow-
ing data: the time from the drug administration to amniotic 
fluid rupture, the time from drug administration to the be-
ginning of the first stage of labor and the time from drug 
administration to vaginal labor or caesarean section, as 
shown in Table 2. 
Table 1. The characteristics of studied groups
Parameter
Dinoprostone 
group 
n (%)
Misoprostol 
group 
n (%)
Sample size 24 26
Parity:
•	 Primigravidas
•	 Multigravidas
 
17 (70%)
7 (30%)
 
15 (58%)
11 (42%)
History of miscarriage (at least one) 2 (8%) 6 (25%)
Indications for labor induction:
•	 The duration of pregnancy  
> 41 weeks pregnancy
•	 Oligohydramnios
•	 No gain of the fetal weight
•	 Abnormal CTG record
•	 Others (cholestasis, 
preeclampsia)
 
19 (80%)
 
1 (4%)
2 (8%)
1 (4%)
1 (4%)
 
19 (73%)
 
3 (11%)
1 (4%)
1 (4%)
2 (8%)
Scheme of the administration:
•	 Only prostaglandins
•	 Prostaglandins with Foley 
catheter
 
13 (54%)
11 (46%)
 
24 (92%)
2 (8%)
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In comparison to dinoprostone, the misoprostol applica-
tion was found to shorten the time from drug administration 
to amniotic fluid rupture by 14.1 hours (Figure 1), the time 
to the beginning of the first stage of labor by 11.7 hours and 
from the drug administration to the delivery by 17.3 hours 
(Figure 2) with 13.4 hours for vaginal delivery and 31.3 hours 
for cesarean section, respectively. The result for dinopros-
tone should be interpreted with caution, as it was calculated 
from four records: 24, 26, 79, 19 hours — and there were only 
four patients to whom cesarean section was performed. The 
power of the tests was above 70%, except for the time after 
drug administration to caesarean section — the small power 
is due to a small number of trials performed, resulting in 
unreliable data, despite the statistical significance. 
Afterwards, the duration times of labor stages I, II and III 
were compared between the dinoprostone and misopros-
tol groups. After removal of three outliers (defined by the 
Grubbs test) and confirming the homogeneity of variance, 
the Student t-test was performed to find the significant dif-
ferences between the study groups — as shown in Table 3.
The duration of the first stage of labor in the misoprostol 
group was shorter by 1.2 hours than in the dinoprostone 
group. However, the duration of the second stage of labor 
was 11 minutes longer in patients undergoing misoprostol 
pre-induction in comparison to dinoprostone pre-induction. 
No differences were observed in the third stage of labor. 
The number of deliveries completed within 24 hours 
from the beginning of drug administration was counted. 
The patients who gave birth within 24 hours accounted for 
76% of the presented population. In dinoprostone group 
Table 2. The results of comparison between the groups — time to endpoint
Parameter Dinoprostone group (hours)
Misoprostol 
group (hours)
Mean 
difference
P value  
(U-Mann-Whitney)
Statistical 
power
The time from drug administration to amniotic fluid 
rupture 23.4 9.3 14.1 (6.0–22.2) 0.0019 75
The time from drug administration to the beginning of 
the first stage of labor 18.5 6.8 11.7 (4.6–18.7) 0.0025 72
The time from drug administration to labor 28.0 10.7 17.3 (9.5–25.1) 0.0000 89
The time from drug administration to vaginal delivery 24.4 10.9 13.4 (5.1–21.8) 0.0041 71
The time from drug administration to caesarean section 41.6 10.3 31.3 (13.3–49.3) 0.0027 51
Table 3. The duration time of labor stages
Parameter Dinoprostone group (time)
Misoprostol 
group (time)
Mean 
difference
P value  
(U-Mann-Whitney)
Statistical 
power
Duration time of I stage of labor (hours) 5.4 4.2 1.2 (0.3–2.2) 0.0126 61
Duration time of II stage of labor (minutes) 12.8 23.9 11.1 (0.3–21.9) 0.0440 32
Duration time of III stage of labor (minutes) 7.5 8.3 0.8 (–0.9–2.7) 0.3503 14
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Figure 1. The time from drug administration to amniotic fluid rupture
Figure 2. The time from drug administration to labor
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it was represented by 54% patients, compared to 100% of 
deliveries in misoprostol group.
The mode of delivery between two study groups was 
compared. Indication for a caesarean section was most of-
ten the threatening fetal asphyxia (60% in the group with 
dinoprostone, 63% in the group with misoprostol) and lack 
of the labor progress (40% in the group with dinoprostone, 
27% in the group with misoprostol). There were 4 caesar-
ean sections performed in the group of patients undergoing 
pre-induction with dinoprostone which accounted for 17% 
of deliveries and compared to the group of misodel group 
wherein 10 caesarean sections were performed accounting 
for 38% of deliveries in this group. This result is not statisti-
cally significant (Chi2 test p = 0.1255) and the trial power 
at 34% level.
The need for the Oxytocin appeared in 52% of cases of 
labor pre-induction scheme using dinoprostone and 16% of 
cases in the scheme based on the misoprostol application.
Epidural during labor was performed in 50% of cases of 
labor pre-induction in the scheme of dinoprostone and 20% 
of cases in the scheme based on the misoprostol application.
There was one case in misoprostol group in which new-
born scored 7 in Apgar scale. In other cases newborns scored 
8 or more points.
DISCUSSION
In the presented material the vast majority of the pa-
tients were eligible for labor induction mainly due to the 
duration of pregnancy more than 41 weeks pregnancy (80% 
and 73% for dinoprostone and misoprostol respectively). 
Before the procedure in each of the patient’s cervix was as-
sessed of less than 4 in the Bishop scale. This is consistent 
with the current guidelines relating to the indications for 
the labor induction [7].
The basic element for evaluating the success of labor 
induction is time to reach the endpoints, in particular the 
contractile function appearance and consequently the de-
livery. Based on the collected material the time from drug 
administration to the contractile function appearance and 
the length of the various stages of labor were calculated. In 
the misoprostol group the effect was achieved significantly 
statistically faster — the time to the contractile function ap-
pearance was shortened by 11 hours, while to the delivery 
by 17 hours in comparison to dinoprostone group. The 
period from the beginning of labor induction to amniotic 
fluid rupture was shorter in misoprostol group. In previ-
ous studies, including large meta-analysis, the results were 
similar to those shown below [8]. Nevertheless, it should 
be noted that in the literature comparisons of exact these 
two types of prostaglandin administration are not available. 
To objectively compare the results the number of de-
liveries completed within 24 hours from the beginning 
of drug administration is taken into consideration. In our 
material all patients in the group of misoprostol delivered 
within 24 hours in contrast to dinoprostone group in which 
approximately half of patients delivered in this period. Be-
cause of the small sample size we were not able to show 
the statistical difference, but this trend is consistent with 
previous reports. One study, where dinoprostone gel and 
misoprostol administered in form of vaginal tablets were 
compared, showed similar effects [9]. However, another 
study with misoprostol in the form of 0.2 mg intravaginal 
insert in numerous population of patients the percentage 
of giving birth within 24 hours was 54.6% [10].
The length of the respective labor stages differed. Inter-
estingly, after the application of misoprostol, the first stage 
was shorter than for dinoprostone by about 1.2 hours, but 
the second stage lasted longer by about 11 minutes. Alas 
due to the small number of patients, the power of the test 
was limited and the improvement of the reliability may be 
increased by enlargement of the population included in the 
study. Given the lack of data on the labor stages in previous 
reports, it is difficult to confront our results. Certainly this 
observation requires further trials.
An important factor in determining not only the ef-
fectiveness, but also the safety of labor induction is the 
percentage of caesarean sections. In the collected material, 
the increased amount of surgical birth was observed in 
misoprostol group (42%) relatively to dinoprostone (21%), 
but the relationship was statistically insignificant. How-
ever, in both groups indications for cesarean section were 
similarly distributed, including threatening fetal asphyxia 
and the lack of the labor progress. In large meta-analysis, 
which took into account the various methods of labor in-
duction, the percentage of caesarean sections was lower in 
misoprostol group 18.2% versus 29.7% for misoprostol and 
dinoprostone respectively and the trend could also be seen 
in other reports [5, 11, 12].
Interestingly, in this study the necessity of giving Oxy-
tocin occurred in nearly half of patients in group induced 
with dinoprostone, meanwhile it concerned only 20% of 
deliveries in misoprostol group and a similar trend was vis-
ible in most reports on the subject [13, 14].
The study also assessed the condition of newborns as 
the sum of Apgar points in 1, 3 and 5 minutes of life. Both in 
misoprostol and dinoprostone group, the condition of new-
borns was satisfactory — the score within the normal range. 
The data presented in this study is consistent with previ-
ous reports, as it was shown above. However, most studies 
show analysis of different modes of induction including 
prostaglandins, none of them compares two methods avail-
able currently in Poland — intracervical administration di-
noprostone gel at a dose of 0.5 mg and intravaginal insert 
of misoprostol at a dose of 0.2 mg. Certainly both methods 
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deserve further observation. This analysis is a pilot study to 
further prospective study which goal is to collect a larger 
population of patients and assess the effectiveness of both 
methods. What is more, the analysis of cardiotocography 
should be included in the study — both on the fetal heart 
rate and pathological uterine contractions, as there were 
reports of increased risk of hypertonia, hyperstimulation and 
tachysystole when administering misoprostol [15].
CONCLUSIONS
The studies on the use of prostaglandin in the labor in-
duction have been carried out for over several decades. Their 
use is particularly valuable in the groups of patients with 
an unprepared cervix. Following proper proceedings they 
are safe for both the mother and the fetus. Yet, there is no 
consensus on the appropriate dosage or timing as the op-
timal form of therapy is still being sought out.
The following factors are mentioned among the predic-
tive factors of successful labor induction: the score in Bishop’s 
scale, parity, body mass index, age, comorbidity, gestational 
age, estimated fetal weight and the experience of staff. Fur-
ther research is therefore reasonable when including such 
factors [16]. The study shown is retrospective and applies to 
a relatively small group, hence comparing these two methods 
on a larger population in a randomized trial is crucial.
Deciding on the appropriate method of labor induction 
is a challenge. Like any medical intervention, labor induction 
should be preceded by a discussion of potential risks and 
benefits of various methods individually.
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